1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)

C Le Péchoux ,P Boisselier,B Lamezec,J Madelaine,A Bardet,D Lerouge,D Antoni,F Thillays,N Pourel,A Paumier,Éric Dansin ,Gérard Zalcman ,Éric Pichon ,Anne Larrouy ,Corinne Faivre-Finn ,Fabrice Barlési ,Ursula Nestle ,Karine Peignaux ,Armelle Lavolle ,Oliver Riesterer

doi:10.1016/j.annonc.2021.08.1774

1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)

C Le Péchoux , P Boisselier + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1774

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 6	License type: publisher-specific-oa

#Post-operative Conformal Radiotherapy #N2 Non-small Cell Lung Cancer Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Primary analysis of Lung ART trial has shown (ESMO 2020) a non-statistically significant effect of PORT on disease-free survival (DFS) in N2 NSCLC patients (HR = 0·86 (95% CI 0·68-1·08]; p=0·18). However PORT was associated with a reduction of 51% in the risk of mediastinal relapse (MR). Patterns of relapse as well as prognostic factors of PORT efficacy warranted further investigations to determine which patients could benefit more from PORT.

Full Text